Improved Method of Detecting Cancer Metastases

Endometrial Carcinoma Clinical Trial

— SITs  

Official title:

Study of Instillation Technique Using The Modified Intra- Uterine Manipulator Catheter With Methylene Blue, Isosulfan Blue or Indocyanine Green Dyes, Compared to Cervical Injection, For Sentinel Lymph Node Detection in Endometrial Carcinoma

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02368067
• Other study ID #: SERMC- Endometrial Carcinoma
• Status: Enrolling by invitation
• Phase: N/A
• First received: November 17, 2014
• Last updated: February 13, 2015
• Start date: June 2014
• Est. completion date: December 2015

Study information

• Verified date: February 2015
• Source: Southeastern Regional Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the Instillation Technique Using The Modified Intra- Uterine Manipulator Catheter With Methylene Blue, Isosulfan Blue or Indocyanine Green Dyes, Compared to Cervical Injection, For Sentinel Lymph Node Detection in Endometrial Carcinoma.

Description:

Following consent, surgery will be determined by the physician thereby determining group assignment- i.e the laparoscopic surgery group oror the robotic assisted surgery group. Both groups will undergo SLN mapping by instillation and injection. The Laparotomy/Laparoscopy Group will have Lymphazurin by injection and instillation of methylene blue dye. The Robot Assisted Group will have ICG by injection and instillation of methylene blue. Patients will undergo total hysterectomy, bilateral salpingoophorectomy, pelvic and paraaortic lymphadenectomy through laparotomy, laparoscopic or robotic assisted surgery as clinically determined by their attending physician. Subjects will undergo this surgery whether or not enrolled in the study.

Any clinically indicated uterine manipulator will be acceptable. Potential subjects will be informed of the potential risks of this device so they may make an informed decision about participation in the study. However the manipulator is standard of care and is not a study related risk. Subjects who agree to this study procedure will be monitored for adverse events.

The dyes used in this study are commercially available and will be provided through internal funding from the CTCA Gynecology/Oncology Department. Potential subjects will be informed

of the potential risks of these drugs so they may make an informed decision about participation in the study. Subjects who agree to this study procedure will be monitored for adverse events.

After administration of anesthesia, the intra-uterine uterine manipulator catheter will be inserted using the following suggested instructions for use;

• After the standard of care vaginal prep with povidone-iodine or any other surgeon preference cleansing solution, expose the cervix using a vaginal speculum. No additional preparation of the cervix is needed.

Immediately following exposure pf the cervix with the speculum, and before introduction of the intra-uterine uterine manipulator with catheter, 4ml total of isosulfan 1% blue or ICG (depending on what route of surgery is being elected) dye will be delivered by cervical injection as follows:

• Using a 20 or 22 gauge spinal needle, inject dye into the cervix at the 12, 3, 6 and 9 o'clock positions.

• Each site will receive approximately 1ml of dye with ½ superficial just under the mucosa and the remainder approximately 1cm deep to the prior injection.

The 22 gauge needles are commercially available and will be provided as routine clinical care. Potential subjects will be informed of the potential risks of injection so they may make an informed decision about participation in the study. Subjects who agree to this study procedure will be monitored for adverse events.

• Introduce the uterine manipulator with catheter trans-cervically until the distal balloon is positioned in the lower portion of the uterus. This is no different from routine clinical care.

Immediately following cervical injection and placement of the uterine manipulator and once intra-abdominal, the first step in surgery will be to occlude both fallopian tubes, as typically done as part of this surgery, using electrocautery devices (e.g. Ligasure) for sealing only the tubes.

Immediately following occlusion of both fallopian tubes, the comparator instillation dye will be instilled into the uterine cavity through the pre-inserted intra-uterine uterine manipulator catheter as follows:

• Insert the clinically selected uterine manipulator as per standard clinical practice.

• Slowly inject the dye through the center uterine cavity catheter access port., Rapid injection of dye could cause high intrauterine pressure resulting in extravasation. Use slow constant pressure to instill the dye. This can be done by the surgical assistant or by the operating surgeon via a long extension tubing.

It is estimated that it may take up to 40 minutes for the dyes to be absorbed by the surrounding tissue and taken up by the lymphatic vessels turning the nodes blue or green. During this time

the surgery will proceed without delay. These study procedures will not increase the estimated total time to perform the surgery.

The surgery will proceed as routine for any sentinel node dissection. Briefly, during regular dissection, visual identification of any dye taken up by any nodes and specific anatomical distributions will be documented using an anatomical documentation sheet.

Visual detection of the methylene and isosulfan blue dye will be done with the investigator's naked eye.

Visual detection of ICG dye will include use of a charge-coupled device (CCD) camera called Spycam equipped with 3 main components (a near-infrared sensitive image intensifier, 16-bit dynamic-range frame transfer CCD camera and light-emitting diodes [LEDs] that is mounted to the robotic surgical instruments. The Spycam will be directed onto the operative field illuminating the fluorescing dye green. The camera is connected to a monitor and images will display on the screen and will be analyzed using digital imaging processing.

Using the clock in the surgery room as a reference, a member of the surgical team will record the exact time elapsed (in minutes) from administration until visual detection of dye is made for each technique. Blue/green nodes will be labeled as sentinel nodes and non-blue/green nodes will be labeled as non-sentinel. Blue/green nodes will also be labeled to describe which dye is being detected (methylene, isosulfan or ICG). Differences in the dye deposition/absorption by each method (injection vs. instillation) will be documented as either detected or not detected in the nodes and channels using color photography in the surgical setting. Continuous monitoring will be done for adverse events during the surgery and post operatively up to time of patient discharge from the hospital.

All node samples will be histopathologically examined with Hematoxylin and Eosin (H&E) and Immunohistochemistry (IHC) staining to detect micro-metastasis. Analysis will compare results of the instillation technique to cervical injection technique in the same subject for sensitivity of SLN mapping, estimating the false negative predictive value, time to detect SLNs, anatomical distributions of the SLNs, and differences in dye absorption using each technique.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 30
• Est. completion date: December 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age: = 18 years old at the time of consent.

• Preoperatively diagnosed endometrial carcinoma of any stage or grade and planned to undergo surgery (laparotomy, laparoscopy or robotic assisted) at IUSCC.

• Medically operable status.

• Ability to understand and willingness to sign a written informed consent and authorization for the release of health information.

Exclusion Criteria:

• Previous radiotherapy.

• Previous retroperitoneal surgery.

• Significant physical limitations preventing proper vaginal examination as determined by the treating physician.

• Personal history of allergy to iodides, iodine or shellfish.

• No clinical indication for intra-uterine manipulator use.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Endometrial Carcinoma
• Endometrial Neoplasms

Intervention

Procedure:
• Standard of Care Sentinal Node Dye
Delivery of sentinal node dye by different routes
• Study Sentinal Node Dye
Patients will receive different types of dye by different routes of administration

Locations

Country	Name	City	State
United States	Southeastern Regional Medical Center	Newnan	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Southeastern Regional Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of sentinel nodes detected by each method.	To determine if the new procedure is better than the current method of sentinal node detection. We will determine which dye and which route is most sensitive for detected metastatic cancer. Each Sentinel node dye and route will be compared to the full node dissection result.	1 Year	No
Secondary	Time to detection of 1st SN by each method.		1 year	No
Secondary	Sensitivity of each method compared to full node dissection.		1 year	No